A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Pharmacovigilance* ; United States Food and Drug Administration* ; Lutetium*/therapeutic use; Algorithms ; Databases as Topic ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Humans ; Male ; Neoplasm Metastasis ; Time Factors

Lutetium-177( ¹⁷⁷ Lu)-PSMA-617 has been approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Our main objective is to elucidate the association between ¹⁷⁷ Lu-PSMA-617 and reported adverse events (AEs) in the FDA Adverse Event Reporting System (FAERS) database. Relevant information regarding ¹⁷⁷ Lu-PSMA-617 usage and reports of AEs was extracted from the FAERS database. The Empirical Bayes Geometric Mean (EBGM), Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), and Bayesian Confidence Propagation Neural Network (BCPNN) with their 95% confidence intervals (CI) were calculated using four algorithms of disproportionality analysis. The pharmacovigilance signals deemed significant across the four algorithms were considered associated with drug use. We collected 6266 unique reports related to ¹⁷⁷ Lu-PSMA-617 usage from the FAERS database. Compared to other drugs, ¹⁷⁷ Lu-PSMA-617 usage was associated with a higher risk of anemia, platelet count decreased, and pancytopenia. In addition to hematologic AEs, consistent high signals were observed for AEs such as dry mouth, laboratory test abnormal, and general physical health deterioration. The analysis based on mCRPC treatment drugs showed that full blood count decreased, general physical health deterioration, and laboratory test abnormal continued to exhibit significant signals. Furthermore, the number of AEs reports for ¹⁷⁷ Lu-PSMA-617 decreased over time, with most reports occurring within one month after drug administration. Our study compiled AEs associated with ¹⁷⁷ Lu-PSMA-617 in real-world drug usage and highlighted its propensity for specific AEs in the context of mCRPC treatment. These findings will contribute to enhancing our clinical experience with this medication.
(© 2024. The Author(s).)

Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024 [J]. CA: a cancer journal for clinicians, 74(1): 12–49 (2024). https://doi.org/10.3322/caac.21820.
Desai, K., Mcmanus, J. M. & Sharifi, N. Hormonal therapy for prostate Cancer [J]. Endocr. Rev. 42 (3), 354–373. https://doi.org/10.1210/endrev/bnab002 (2021). (PMID: 10.1210/endrev/bnab002334809838152444)
Ge, R. et al. Epigenetic modulations and lineage plasticity in advanced prostate cancer [J]. Annals oncology: official J. Eur. Soc. Med. Oncol. 31 (4), 470–479. https://doi.org/10.1016/j.annonc.2020.02.002 (2020). (PMID: 10.1016/j.annonc.2020.02.002)
Banerjee, S., Pillai, M. R. & Knapp, F. F. Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications [J]. Chem. Rev. 115 (8), 2934–2974. https://doi.org/10.1021/cr500171e (2015). (PMID: 10.1021/cr500171e25865818)
Violet, J. et al. Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: Correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes [J. J. Nucl. Med. Off. Publ. Soc. Nuclear Med. 60 (4), 517–523. https://doi.org/10.2967/jnumed.118.219352 (2019). (PMID: 10.2967/jnumed.118.219352)
Current, K. et al. Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity [J]. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 26 (12), 2946–2955. https://doi.org/10.1158/1078-0432.Ccr-19-1485 (2020). (PMID: 10.1158/1078-0432.Ccr-19-1485)
Afshar-Oromieh, A. et al. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions [J]. J. Nucl. Med. Off. Publ. Soc. Nuclear Med. 56 (11), 1697–1705. https://doi.org/10.2967/jnumed.115.161299 (2015). (PMID: 10.2967/jnumed.115.161299)
Patell, K. et al. Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review [J]. Expert Rev. Anticancer Ther. 23 (7), 731–744. https://doi.org/10.1080/14737140.2023.2213892 (2023). (PMID: 10.1080/14737140.2023.221389237194261)
Sartor, O. et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer [J]. N. Engl. J. Med. 385 (12), 1091–1103. https://doi.org/10.1056/NEJMoa2107322 (2021). (PMID: 10.1056/NEJMoa2107322341610518446332)
Dhodapkar, M. M. et al. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study [J]. BMJ (Clinical Res. ed), 379, e071752. https://doi.org/10.1136/bmj-2022-071752 (2022).
Michel, C. et al. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles? [J]. Clin. Drug Investig. 37 (5), 415–422. https://doi.org/10.1007/s40261-017-0503-6 (2017). (PMID: 10.1007/s40261-017-0503-628224371)
Weaver, J. et al. Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA) [J]. Dermatol. Ther. 22 (3), 204–215. https://doi.org/10.1111/j.1529-8019.2009.01233.x (2009). (PMID: 10.1111/j.1529-8019.2009.01233.x19453344)
Psaty, B. M. & Siscovick, D. S. Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction [J]. Jama. 304 (8), 897–898. https://doi.org/10.1001/jama.2010.1205 (2010). (PMID: 10.1001/jama.2010.120520736474)
Bate, A. & Evans, S. J. Quantitative signal detection using spontaneous ADR reporting [J]. Pharmacoepidemiol. Drug Saf. 18 (6), 427–436. https://doi.org/10.1002/pds.1742 (2009). (PMID: 10.1002/pds.174219358225)
Elisabetta, P. et al. Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS) [M]//ADEM K. Data Mining Applications in Engineering and Medicine. Rijeka; IntechOpen. : Ch. 12. (2012). https://doi.org/10.5772/50095.
Huynh-Le, M. P. et al. Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization [J]. Clin. Genitourin. Cancer, 18(3): 192–200e192. https://doi.org/10.1016/j.clgc.2019.11.017 (2020).
Van Puijenbroek, E. P. et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions [J]. Pharmacoepidemiol. Drug Saf. 11 (1), 3–10. https://doi.org/10.1002/pds.668 (2002). (PMID: 10.1002/pds.66811998548)
Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports [J]. Pharmacoepidemiol. Drug Saf. 10 (6), 483–486. https://doi.org/10.1002/pds.677 (2001). (PMID: 10.1002/pds.67711828828)
Dumouchel, W. Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System [J]. Am. Stat. 53 (3), 177–190. https://doi.org/10.1080/00031305.1999.10474456 (1999). (PMID: 10.1080/00031305.1999.10474456)
Bate, A. et al. A Bayesian neural network method for adverse drug reaction signal generation [J]. Eur. J. Clin. Pharmacol. 54 (4), 315–321. https://doi.org/10.1007/s002280050466 (1998). (PMID: 10.1007/s0022800504669696956)
Schaeffer, E. M. et al. NCCN Guidelines ^® Insights: Prostate Cancer, Version 3.2024 [J]. J. Natl. Compr. Cancer Network: JNCCN. 22 (3), 140–150. https://doi.org/10.6004/jnccn.2024.0019 (2024). (PMID: 10.6004/jnccn.2024.001938626801)
Tilki, D. et al. Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer [J]. Eur. Urol. 86 (2), 164–182. https://doi.org/10.1016/j.eururo.2024.04.010 (2024). (PMID: 10.1016/j.eururo.2024.04.01038688773)
Chi, K. N. et al. Safety Analyses of the Phase 3 VISION Trial of [(177)Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer [J]. Eur. Urol. 85 (4), 382–391. https://doi.org/10.1016/j.eururo.2023.12.004 (2024). (PMID: 10.1016/j.eururo.2023.12.00438185538)
Almuradova, E. et al. The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study [J]. Int. J. Cancer. 154 (4), 692–700. https://doi.org/10.1002/ijc.34749 (2024). (PMID: 10.1002/ijc.3474937818966)
Hofman, M. S. et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial [J]. Lancet (London England). 397 (10276), 797–804. https://doi.org/10.1016/s0140-6736(21)00237-3 (2021). (PMID: 10.1016/s0140-6736(21)00237-333581798)
Zhang, X. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer [J]. Cancer Commun. (London England). 39 (1), 76. https://doi.org/10.1186/s40880-019-0425-1 (2019). (PMID: 10.1186/s40880-019-0425-1)
Kabasakal, L. et al. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer [J]. Eur. J. Nucl. Med. Mol. Imaging. 42 (13), 1976–1983. https://doi.org/10.1007/s00259-015-3125-3 (2015). (PMID: 10.1007/s00259-015-3125-326227531)
Fisher, D. R. Perspectives on Internal Dosimetry for Optimized Radionuclide Therapy [J]. Cancer Biother. Radiopharm. 37 (3), 161–163. https://doi.org/10.1089/cbr.2021.0318 (2022). (PMID: 10.1089/cbr.2021.031834569812)
Fizazi, K. et al. Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial [J]. Lancet Oncol. 24 (6), 597–610. https://doi.org/10.1016/s1470-2045(23)00158-4 (2023). (PMID: 10.1016/s1470-2045(23)00158-43726984110641914)
Sakaeda, T. et al. Data mining of the public version of the FDA Adverse Event Reporting System [J]. Int. J. Med. Sci., 10(7): 796–803. https://doi.org/10.7150/ijms.6048 (2013).
Patnaik, S. et al. Metastatic spinal cord compression [J]. British journal of hospital medicine (London, England: 2020, 81(4): 1–10. DOI: (2005). https://doi.org/10.12968/hmed.2019.0399.
Fox, P. C. Acquired salivary dysfunction. Drugs and radiation [J]. Ann. N. Y. Acad. Sci. 842, 132–137. https://doi.org/10.1111/j.1749-6632.1998.tb09641.x (1998). (PMID: 10.1111/j.1749-6632.1998.tb09641.x9599303)

TJSJMYXYC-D2-026 Tianjin Municipal Health Commission

0 (Pluvicto)
5H0DOZ21UJ (Lutetium)

Date Created: 20241029 Date Completed: 20250204 Latest Revision: 20250204

20250204

PMC11519899

10.1038/s41598-024-77889-3

39468291